SCHEMBL8302429

SCHEMBL8302429

CCOC(=O)c1nn(C)cc1[N+](=O)[O-]

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.61
MEN1 O00255 1/20 0.61
POLB P06746 1/20 0.61
KMT2A Q03164 1/20 0.61
L3MBTL1 Q9Y468 2/20 0.55
ADORA3 P0DMS8 1/20 0.52
ADORA2A P29274 1/20 0.52
ADORA1 P30542 1/20 0.52
MAPT P10636 2/20 0.51
PTGS1 P23219 1/20 0.49
PTGS2 P35354 1/20 0.49
MITF O75030 2/20 0.48
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
HTT P42858 1/20 0.46
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7515726 0.85 ALDH1A1 (0.60) LMNAMEN1POLBKMT2AL3MBTL1
SCHEMBL1558732 0.84 L3MBTL1 (0.60) LMNAMEN1POLBKMT2AL3MBTL1
SCHEMBL7517984 0.83 MEN1 (0.48) LMNAMEN1POLBKMT2AL3MBTL1
SCHEMBL7511754 0.81 POLB (0.44) LMNAMEN1POLBKMT2AL3MBTL1
SCHEMBL7522071 0.80 NPC1 (0.67) LMNAMEN1POLBKMT2AMAPT
SCHEMBL7513311 0.80 POLB (0.46) LMNAMEN1POLBKMT2AL3MBTL1
SCHEMBL1459312 0.79 ADORA2A (0.55) LMNAPOLBADORA3ADORA2AADORA1
SCHEMBL2516609 0.79 ADORA2A (0.55) LMNAMEN1POLBKMT2AADORA3
SCHEMBL7511662 0.79 ALDH1A1 (0.47) LMNAMEN1POLBKMT2AL3MBTL1
SCHEMBL23248596 0.79 L3MBTL1 (0.58) LMNAMEN1POLBKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119119033-A Pyrazolopyridone compounds 百济神州有限公司 2024-12-13 CN disclosed
US-20180201622-A1 Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2018-07-19 US disclosed
US-9969748-B2 Fused bicyclic heteroaromatic derivatives as kinase inhibitors UCB BIOPHARMA SPRL (BE) 2018-05-15 US disclosed
US-20170129905-A1 Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors UCB BIOPHARMA SPRL (BE) 2017-05-11 US disclosed
EP-3157923-A1 FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS UCB Biopharma SPRL (BE) 2017-04-26 EP disclosed
WO-2016164754-A1 FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-10-13 WO disclosed
WO-2016164703-A1 FGFR4 INHIBITORS EISAI R & D MANAGEMENT CO., LTD. (JP) 2016-10-13 WO disclosed
WO-2015193168-A1 FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2015-12-23 WO disclosed
US-9078899-B2 Pyrazolyl-based carboxamides II GRUENENTHAL GMBH (DE) 2015-07-14 US disclosed
US-9078899-B2 Pyrazolyl-based carboxamides II GRUENENTHAL GMBH (DE) 2015-07-14 US disclosed
WO-2014108336-A1 PYRAZOLYL-BASED CARBOXAMIDES II AS CRAC CHANNEL INHIBITORS Grünenthal GmbH (DE) 2014-07-17 WO disclosed
US-20140194452-A1 Pyrazolyl-Based Carboxamides II Grünenthal GmbH (DE) 2014-07-10 US disclosed
US-20140194452-A1 Pyrazolyl-Based Carboxamides II Grünenthal GmbH (DE) 2014-07-10 US disclosed
US-7566708-B2 Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-07-28 US disclosed
US-7435731-B2 Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same ROCHE PALO ALTO LLC (US) 2008-10-14 US disclosed
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-08-30 US disclosed
WO-2005002552-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180201622-A1 Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors PI4KB, PI4KA, PI4K2B LMNA 4764/4885MEN1 3632/4885POLB 1154/4885
US-20140194452-A1 Pyrazolyl-Based Carboxamides II AADAC, VDAC2, NLRP3 LMNA 1662/4885MEN1 4248/4885POLB 2453/4885
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same MAPKAPK2, MAPK1, MAP3K2 LMNA 2067/4885MEN1 4341/4885POLB 718/4885
US-20170129905-A1 Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors PI4KB, PI4KA, PI4K2B LMNA 4764/4885MEN1 3632/4885POLB 1154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.